Chinese Hepatolgy ›› 2022, Vol. 27 ›› Issue (6): 703-707.

• Other Liver Diseases • Previous Articles     Next Articles

The clinical efficacy of ursodeoxycholic acid in the treatment of infantile cholestatic hepatitis and its influence on serum inflammation indicators and intestinal flora

LIU Xi, LIAO Shan, LIU Xiao-guai   

  1. Department of Infection, Xi’an City of Children’s Hospital, Shaanxi 710003,China
  • Received:2021-12-12 Online:2022-06-30 Published:2022-08-04
  • Contact: LIU Xiao-guai, Email:xiaoguai760725@126.com

PDF (PC)

259

Abstract: Objective To explore the clinical value of ursodeoxycholic acid (UDCA) in infantile cholestatic hepatitis (ICH).Methods 186 infants with ICH were selected as observation objects and grouped by random number table method. The control group (93 cases) took oral preparations of live bifidobacteria, and the observation group (93 cases) took UDCA on the basis of the control group, for 2 weeks of treatment. The indicator changes of serum inflammation factors [Interleukin-4 (IL-4), IL-6, IL-10 and tumor necrosis factor-α (TNF-α)], liver function [alkaline plum phosphate (ALP), total bilirubin (TBil), alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT)], immunoregulatory factors and bile acid indicators [soluble vascular cell adhesive molecule-1 (sVCAM-1), conjugated bile acid (CBA) and cholyglycine (CG)], intestinal flora [Lactobacillus, Bifidobacteria, Escherichia coli, and the ratio of Bifidobacteria to Enterobacteria (B/E) value)] before and 2 weeks after the medication were observed, and clinical efficacy and safety were assessed.Results The expression levels of serum IL-4 and IL-10 increased, and the expression levels of IL-6 and TNF-α decreased (P<0.05) after 2 weeks of treatment. And the levels of IL-4 and IL-10 in the observation group were significantly higher than those in the control group (P<0.05), the levels of IL-6 and TNF-α in the observation group were significantly lower than those in the control group (P<0.05). The levels of ALP, ALT, TBil, GGT, sVCAM-1, CBA, and GG in the two groups of infants were reduced after 2 weeks (P<0.05), and the levels of ALP, ALT, TBil, GGT, sVCAM-1, CBA and GG in the observation group were significantly lower than those in the control group (P<0.05). The numbers of Bifidobacteria, Lactobacillus and B/E value increased in the two groups after two weeks of medication, and the numbers of Bifidobacteria, Lactobacillus and B/E value in the observation group were significantly higher than those of the control group (P<0.05). The numbers of Escherichia coli (E. coli) in the two groups after two weeks of medication decreased (P<0.05), but there was no significant change in the numbers of E. coli in the observation group compared with the control group after 2 weeks of treatment (P>0.05). The total effective rate of treatment in the observation group was 94.62%, which was significantly higher than 86.02% in the control group (χ2=4.230, P<0.05). The adverse reaction rate of the observation group was 6.45%, compared with 5.38% of the control group, there was no significant difference (χ2=0.103, P>0.05).Conclusion UDCA has outstanding efficacy in treating ICH, which can inhibit inflammation, promote the recovery of intestinal flora, and improve liver function. Its mechanism may be related to the regulation of sVCAM-1 and bile acid indicators, and it is safe to use.

Key words: Ursodeoxycholic acid, Infantile cholestatic hepatitis, Inflammation, Bile acids